3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
3
Breast Neoplasms
2
Solid Tumours
1
Side-effect of Antibiotic
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Long QT Syndrome
1
Hot Flashes
1
Hodgkin Disease
1
Carcinoma, Renal Cell
1
Bacteremia
1
Advanced Breast Cancer
1
Interventions
Sunitinib
86
Sorafenib
60
Everolimus
47
pazopanib
46
Bevacizumab
46
Nivolumab
44
pembrolizumab
37
aldesleukin
29
Interferon-alpha
26
Axitinib
24
temsirolimus
23
cabozantinib
20
Interleukin-2
19
Ipilimumab
16
Interferon alpha-2
15
Cyclophosphamide
15
fludarabine phosphate
14
Gemcitabine
14
Peripheral Blood Stem Cell Transplantation
11
Sirolimus
10
Paclitaxel
10
Erlotinib Hydrochloride
10
avelumab
8
Radiosurgery
8
Docetaxel
8
Cyclosporine
8
Capecitabine
8
tremelimumab
7
lenvatinib
7
Mycophenolic Acid
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Renal Cell
×
Moxifloxacin
×
Clear all
NCT00861029
2017-11-14
VEG111485: A QTc Study of Pazopanib
GlaxoSmithKline
Phase 1
Completed
2 enrolled